Evidence map›Paper›PMID 34983129›Full record

ArticleInvestigative and clinical urology2022

Identification of adhesion-associated extracellular matrix component thrombospondin 3 as a prognostic signature for clear cell renal cell carcinoma.

Xiangling Chen, Jiatian Lin, Min Chen, Qiaoling Chen, Zhiming Cai, Aifa Tang

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Investigative and clinical urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Super-Enhancer DrivesAnimals : an open access journal from MDPI · 2025
    Article
  2. Article
  3. Matricellular proteins in cutaneous wound healing.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Xiangling Chen *Guangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen Institute of Translational Medicine, Shenzhen, China.ORCID 0000-0002-4986-9423
Jiatian Lin *Department of Minimally Invasive Intervention, Peking University Shenzhen Hospital, Shenzhen, China.ORCID 0000-0001-5274-4894
Min ChenState Key Laboratory of Cell Biology, CAS Key Laboratory of Systems Biology, CAS Center for Excellence in Molecular Cell Science, Innovation Center for Cell Signaling Network, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0002-0254-1535
Qiaoling ChenDepartment of Biology, NO. 6 Middle School of Changsha, Changsha, China.ORCID 0000-0002-2653-8402
Zhiming CaiGuangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen Institute of Translational Medicine, Shenzhen, China.ORCID 0000-0002-2966-4367
Aifa TangGuangdong Provincial Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen Institute of Translational Medicine, Shenzhen, China.ORCID 0000-0002-7516-0506
Shenzhen Second People's Hospital · CNCenter for Excellence in Molecular Cell Science · CNChangsha University · CNPeking University Shenzhen Hospital · CNShenzhen Institutes of Advanced Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClear cell renal cell carcinoma (ccRCC) is a highly aggressive disease, and approximately 30% of patients are diagnosed at the metastatic stage. Even with targeted therapies, the prognosis of advanced ccRCC is poor. The aim of this study was to investigate clinical prognosis signatures by analyzing the ccRCC datasets in The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the function of thrombospondin 3 ( MATERIALS AND

methodsWe analyzed the ccRCC datasets in TCGA and CPTAC to search for extracellular matrix (ECM)-related and adhesion-associated genes, and conducted overall survival, Cox, and receiver operating characteristic analyses. We also performed CCK8, colony formation, and transwell assays to compared the proliferation and migration ability of

resultsComprehensive bioinformatics analysis revealed that

conclusionsIn summary, our data have revealed that

Indexed as

Carcinoma, Renal CellExtracellular MatrixFemaleHumansKidney NeoplasmsMalePrognosisThrombospondinsTumor Cells, Culturedthrombospondin 3ThrombospondinsClear cell renal cell carcinomaHumanMetastasisThrombospondin 3 protein

Identifiers

PMID34983129
PMCPMC8756151
OpenAlexW3205234789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.